Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.
A study was designed to determine the interactions, both clinical and pharmacokinetic, between methadone and lopinavir-ritonavir. Results demonstrated a 36% reduction in the methadone area under the plasma concentration-time curve after the introduction of lopinavir-ritonavir, with no coincident symptoms of opioid withdrawal and no requirement for methadone dose adjustment.
Clarke
Susan
S
GenitoUrinary Medicine and Infectious Diseases Clinic, St. James's Hospital, Dublin, Ireland. Susan.Clarke@bmc.org
Mulcahy
Fiona
F
Bergin
Colm
C
Reynolds
Helen
H
Boyle
Nicola
N
Barry
Michael
M
Back
David J
DJ
D000328:Adult; D000701:Analgesics, Opioid / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D061466:Lopinavir; D008297:Male; D008691:Methadone / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D009293:Opioid-Related Disorders / Q000209:etiology; D011744:Pyrimidinones / Q000494:pharmacology / Q000627:therapeutic use; D012367:RNA, Viral / Q000187:drug effects; D019438:Ritonavir / Q000494:pharmacology / Q000627:therapeutic use; D013375:Substance Withdrawal Syndrome / Q000209:etiology*
D000701:Analgesics, Opioid; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D012367:RNA, Viral; D061466:Lopinavir; D019438:Ritonavir; D008691:Methadone